davunetide intranasal (AL-108) / Endo  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
davunetide intranasal (AL-108) / Endo
NCT00422981: Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

Completed
2
144
US
AL-108, Placebo
Allon Therapeutics
Mild Cognitive Impairment, So Stated
01/08
01/08
NCT00505765: A Multicenter Study of NAP (AL-108) in Schizophrenia

Checkmark In patients with schizophrenia; N=63
Jan 2013 - Jan 2013: In patients with schizophrenia; N=63
Checkmark P2 data
Dec 2011 - Dec 2011: P2 data
Completed
2
63
US
AL-108, Placebo
University of California, Los Angeles, University of Maryland, Washington University School of Medicine, Massachusetts General Hospital, Nathan Kline Institute for Psychiatric Research, Columbia University, Duke University, Beth Israel Deaconess Medical Center
Schizophrenia
04/09
04/09

Download Options